How bad was that original risk-share? Sanofi had to threaten to remove their therapy from the PBS for atopic dermatitis to secure any changes, and it remains so bad that Lilly is not going to list EBGLYSS. …
This could be the canary in the coal mine, but a lot of canaries have already died
June 15, 2025 Latest NewsBioPharmaComment
Latest Video
Georgia Forrest
New Stories
-
ViiV invests in HIV-focused initiatives through Positive Action Community Grants program
February 9, 2026 - - Latest News -
A 'meeting of minds' and the risk of not being able to 'unknow' information
February 9, 2026 - - Latest News -
Women’s health reforms deliver savings and expanded access one year on
February 9, 2026 - - Latest News -
A new option for Kiwis with Lilly confirming Mounjaro launch in New Zealand
February 9, 2026 - - Latest News -
The race for the Pharma Cup heats up as teams chase the summit
February 8, 2026 - - Latest News -
The leaders will be thinking about this situation like a game of chess
February 7, 2026 - - Latest News -
TrumpRx launches based on global pricing promise in an insurance-dominated reality
February 7, 2026 - - Latest News